Tamtam Try Tamtam free
Novanta Inc. logo

Novanta Inc. account plan

Precision technology solutions provider

At a glance

Novanta supplies components and sub-systems to medical, life science and advanced industrial OEMs, with FY2025 revenue of $980.6 million.

Novanta Inc., founded in 1968 as General Scanning and organised as a holding company in Canada, engineers components and sub-systems that medical, life science and advanced industrial OEMs build into their own systems, sold mostly through a direct technical sales force. FY2025 revenue was $980.6 million (+3.3%), with operating income of $94.0 million and net income of $53.8 million; the medical market was approximately 53% of revenue and the United States 52.9%. It had about 3,000 employees at 31 December 2025, approximately 36% in the United States, 55% in Europe and 9% in Asia. Customer concentration is high: the top ten customers made up approximately 42% of 2025 sales. The July 2026 acquisition of Riverpoint Medical, the largest in its history, raises its medical share further.

Business units

Strategic priorities

More medical, more recurring
Management steers toward medical end markets, now 53% of revenue and approaching 60% on a full-year basis with Riverpoint, and recurring consumables, roughly 25% of revenue.
Organic growth through new products
Long-term algorithm of mid to high single-digit organic growth; new product revenue rose 23% in Q3 2026 and advanced surgery targets approximately $400 million in revenue by 2030.
Deleveraging after Riverpoint
The near-term capital deployment priority is to delever; net leverage stood at 2.2 at the end of Q3 2026.
Regional manufacturing footprint
Regionalize manufacturing into centers of excellence and go from 21 to 18 factories by end of Q1 2027, under a restructuring program costing about $25.0 million in total by end-2026.
Physical AI and robotics
Grow in robotics, which management describes as a roughly $2 billion addressable market growing about 10% a year, including warehouse automation and humanoids.

Latest results

In Q3 2026 (quarter ended 2 October 2026) revenue rose 23.1% to $305.0 million, with Riverpoint Medical adding $32.9 million and organic growth of nearly 10%. Automation Enabling Technologies grew 16.0% to $145.4 million with a 50.2% gross margin, while Medical Solutions grew 30.3% to $159.7 million but its gross margin fell to 39.9%. Operating income fell 36.3% to $13.9 million on acquisition, restructuring and amortization costs, while adjusted EBITDA rose 38% to $80 million. Backlog was $543 million. Full-year 2026 guidance is revenue of $1,135-1,140 million, adjusted EBITDA of $274-277 million and operating cash flow of about $200 million, with a production slowdown at the Stockport (U.K.) factory weighing on Q4 margins.

Investments and deals

Riverpoint Medical
Minimally invasive surgical consumables maker acquired on 23 July 2026 for $1,200.6 million upfront net of cash, plus a $250.0 million milestone payable by 8 January 2027.
Keonn Technologies
Barcelona RFID specialist acquired on 8 April 2025 for EUR 64.8 million ($71.0 million) net of cash, with up to EUR 20.0 million contingent consideration.
Acquisition funding
$613.1 million net from 6.50% tangible equity units in November 2025, a $300 million private placement at $140.00 per share in June 2026, and a $200.0 million delayed draw term loan.
New financial and operations system
A new ERP system is being implemented, with SAP MRP live at two lighthouse sites; it was a cost driver in 2025.
China spindle capacity
A customer-co-funded China expansion for air bearing spindles should be fully ramped by April 2027.

Challenges and risks

Customer concentration
Two medical OEMs represented approximately 12% and 11% of 2025 revenue and the top ten customers approximately 42%.
Factory transfers and margins
Regional manufacturing transfers created dual running costs; the Stockport production slowdown is roughly a 200 basis point gross margin headwind in Q4 2026.
Component and rare-earth supply
Shortages of components from AI-related demand, Chinese export licences on rare-earth materials and magnets, tariffs, and higher energy and freight costs from the 2026 Iran conflict.
Higher leverage
Riverpoint was funded with $616.0 million of revolver and delayed draw borrowings, taking leverage to 2.43 against a 4.00 covenant.
Precision medicine softness
Precision medicine sales fell 5% in Q3 2026 and life science volume is lower; a return to growth is expected in late 2027.

What leadership says

“more medical, more recurring, and less cyclical”

Matthijs Glastra, Chair and CEO · Q3 2026 earnings call, November 10, 2026

“Our near-term capital deployment priority is to delever”

Matthijs Glastra, Chair and CEO · Q3 2026 earnings call, November 10, 2026

“A design win in one business becomes the invitation into the next.”

Matthijs Glastra, Chair and CEO · Q3 2026 earnings call, November 10, 2026

“Operating in region for region with a supply base close to our factories and our customers is proving to be a real advantage.”

Robert Buckley, CFO · Q3 2026 earnings call, November 10, 2026

Where a supplier can help

Regional supply base
The regional manufacturing footprint and tight rare-earth and electronic component supply create demand for in-region suppliers of magnets, electronic components and materials close to Novanta factories.
Factory consolidation support
Closing factories down to 18 and the Stockport slowdown point to needs in manufacturing transfer, quality testing and production engineering services.
ERP and operations systems
The ongoing financial and operations system implementation, with SAP MRP at lighthouse sites, opens room for ERP integrators and supply-chain planning tools.
Riverpoint integration
Integrating the largest acquisition in its history while deleveraging favours integration, procurement savings and medical consumables manufacturing partners.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Novanta Inc.?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Novanta Inc.

What does Novanta do?

Novanta engineers components and sub-systems, such as laser beam steering, precision motion, robotic tooling, surgical insufflators, pumps and consumables, that medical, life science and advanced industrial OEMs integrate into their own systems.

What is Novanta's revenue?

FY2025 revenue was $980.6 million, up 3.3%. Novanta guides to 2026 revenue of $1,135-1,140 million, including Riverpoint Medical.

How many employees does Novanta have?

Novanta had about 3,000 employees at 31 December 2025, approximately 36% in the United States, 55% in Europe and 9% in Asia.

Who leads Novanta?

Matthijs Glastra is Chair of the Board and CEO, Robert Buckley is CFO, and John Lesica and Chuck Ravetto are Co-Chief Operating Officers.

What is Novanta's strategy?

Become more medical, more recurring and less cyclical through new products, medical acquisitions such as Riverpoint Medical, and a regionalized manufacturing footprint, while delevering in the near term.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)